Мы используем файлы cookie.
Продолжая использовать сайт, вы даете свое согласие на работу с этими файлами.
Experimental drugs
NNI-351
Другие языки:

    NNI-351

    Подписчиков: 0, рейтинг: 0
    NNI-351
    NNI-351.svg
    Clinical data
    Routes of
    administration    		 By mouth
    Identifiers
    • 4-(3-Cyano-6-ethoxyquinolin-2-yl)-N-(2-fluorophenyl)-1,4-diazepane-1-carbothioamide
    CAS Number
    PubChem CID
    ChemSpider
    UNII
    Chemical and physical data
    Formula C24H24FN5OS
    Molar mass 449.55 g·mol−1
    3D model (JSmol)
    • CCOC1=CC2=C(C=C1)N=C(C(=C2)C#N)N3CCCN(CC3)C(=S)NC4=CC=CC=C4F
    • InChI=1S/C24H24FN5OS/c1-2-31-19-8-9-21-17(15-19)14-18(16-26)23(27-21)29-10-5-11-30(13-12-29)24(32)28-22-7-4-3-6-20(22)25/h3-4,6-9,14-15H,2,5,10-13H2,1H3,(H,28,32)
    • Key:RQXUPDSAFGWKMO-UHFFFAOYSA-N

    NNI-351 is an orally active inhibitor of DYRK1A and neurogenesis enhancer which is under development by NeuroNascent, Inc. for the treatment of Down syndrome, depression, and post-traumatic stress disorder (PTSD). As of 2017, it is in the preclinical development stage, and has yet to progress to human clinical trials. In July of 2022, NNI-351 was granted Orphan Drug status by the FDA for the treatment of Fragile X syndrome.

    See also

    External links



    Новое сообщение